Venetoclax (ABT-199), a representative BH3 mimic, is used for chemotherapy of hematologic malignancies including acute myeloid leukemia (AML) that shows high expression of BCL-2 (Souers et al. 2013; Konopleva et al. 2016; Campos et al. 2018; Fleischmann et al. 2022). This evidence concerns the gene BCL2 and acute myeloid leukemia.